Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
REGISTER
The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. Content within the patient forum is user-generated and has not been reviewed by medical professionals. Other sections of the Melanoma Research Foundation website include information that has been reviewed by medical professionals as appropriate. All medical decisions should be made in consultation with your doctor or other qualified medical professional.

Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

› Forums › General Melanoma Community › Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

  • Post
Viewing 1 reply thread
  • Replies
      • July 20, 2011 at 10:23 pm
      James from Sydney
      Participant

      thanks for that info. I wonder if they will now do a Trial to see if adding Dacarbazine to Ippi makes a difference. This Trial compares Dacarbazine alone with Dacarbazine and  Ippi.

      It would be interesting to see if there was a Trial comparing Dacarbazine alone and Ippi alone to see if the stats were similar to the Trial posted. Maybe they will do Ippi alone vs Ippi and Dacabazine.

      best wishes

      James

      • July 20, 2011 at 10:23 pm
      James from Sydney
      Participant

      thanks for that info. I wonder if they will now do a Trial to see if adding Dacarbazine to Ippi makes a difference. This Trial compares Dacarbazine alone with Dacarbazine and  Ippi.

      It would be interesting to see if there was a Trial comparing Dacarbazine alone and Ippi alone to see if the stats were similar to the Trial posted. Maybe they will do Ippi alone vs Ippi and Dacabazine.

      best wishes

      James

        • July 20, 2011 at 10:40 pm
        jim Breitfeller
        Participant

        James,

        Patients with metastatic melanoma have a poor prognosis with a 5 year survival rate of about 5%1. There are two FDA approved treatments for these patients.

        Dacarbazine has an objective  response rate of approximately 12% with 2-3 % complete responses that are often transient2.

        Interleukin-2 (IL-2) has an objective response rate of approximately 15% with 4-5% durable complete responses3.

        Results of two new experimental agents have recently been reported for the treatment of patients with this disease.

        Ipilimumab, an antibody against the inhibitory lymphocyte receptor, CTLA4, mediated a 3.6 month improvement in median survival with an objective response rate of 7% in 540 patients but only three patients (0.6%) achieved a complete regression4.

         PLX4032, an inhibitor of mutated BRAF, had an objective response rate of 77% in 48 patients with 3 (6%) complete regressions5.

        The very small number of durable complete responses make it unlikely that many patients with metastatic melanoma will be cured utilizing any of these approaches.

        This is why we must try combinatorial Therapy

         

        Jimmy B

        • July 20, 2011 at 10:40 pm
        jim Breitfeller
        Participant

        James,

        Patients with metastatic melanoma have a poor prognosis with a 5 year survival rate of about 5%1. There are two FDA approved treatments for these patients.

        Dacarbazine has an objective  response rate of approximately 12% with 2-3 % complete responses that are often transient2.

        Interleukin-2 (IL-2) has an objective response rate of approximately 15% with 4-5% durable complete responses3.

        Results of two new experimental agents have recently been reported for the treatment of patients with this disease.

        Ipilimumab, an antibody against the inhibitory lymphocyte receptor, CTLA4, mediated a 3.6 month improvement in median survival with an objective response rate of 7% in 540 patients but only three patients (0.6%) achieved a complete regression4.

         PLX4032, an inhibitor of mutated BRAF, had an objective response rate of 77% in 48 patients with 3 (6%) complete regressions5.

        The very small number of durable complete responses make it unlikely that many patients with metastatic melanoma will be cured utilizing any of these approaches.

        This is why we must try combinatorial Therapy

         

        Jimmy B

        • July 20, 2011 at 11:07 pm
        James from Sydney
        Participant

        Jimmy thanks for the Stats. I was surprised at the Ippi figures i had thought it was much higher.

        best wishes

        James

        • July 20, 2011 at 11:07 pm
        James from Sydney
        Participant

        Jimmy thanks for the Stats. I was surprised at the Ippi figures i had thought it was much higher.

        best wishes

        James

Viewing 1 reply thread
  • You must be logged in to reply to this topic.
About the MRF Patient Forum

The MRF Patient Forum is the oldest and largest online community of people affected by melanoma. It is designed to provide peer support and information to caregivers, patients, family and friends. There is no better place to discuss different parts of your journey with this cancer and find the friends and support resources to make that journey more bearable.

The information on the forum is open and accessible to everyone. To add a new topic or to post a reply, you must be a registered user. Please note that you will be able to post both topics and replies anonymously even though you are logged in. All posts must abide by MRF posting policies.

Popular Topics